University Hospital Mannheim

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation1 trial
• Childhood cancers1 trial
• Follicular lymphoma1 trial
• Glioblastoma1 trial
• Myeloproliferative neoplasms1 trial
• Obesity1 trial
• Prostate cancer1 trial

Phase

• Phase 23 trials
• Phase 31 trial

Status

• Recruiting4 trials
• Active, not recruiting2 trials
• Completed2 trials

Lead sponsor

• Incyte Corporation3 trials
• Jena University Hospital1 trial
• Universitätsklinikum Hamburg-Eppendorf1 trial
• Universitätsmedizin Mannheim1 trial
• University Hospital, Bonn1 trial
• and 1 more

Running trials

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

  NCT06388564· Phase 2· Incyte Corporation· Source

• Recruiting

  AI-POD Clinical Validation Study for Obese Patients

  NCT06595134· University Hospital, Bonn· Source

  Contact: Stefan Schönberg, Prof. Dr.

• Recruiting

  PROCARE - PROstate Cancer Real World Evidence Registry

  NCT06835218· UroTrials Company (GmbH)· Source

  Contact: Karl Kowalewski, Professor

• Recruiting

  Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.

  NCT04298723· Jena University Hospital· Source

  Contact: Ibrahim Akin, Prof. Dr.

• Active, not recruiting

  Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

  NCT02685605· Phase 3· Universitätsmedizin Mannheim· Source

• Recruiting

  International HIT-MED Registry (I-HIT-MED)

  NCT02417324· Universitätsklinikum Hamburg-Eppendorf· Source

  Contact: Stefan Rutkowski, Prof.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Phase 2· Incyte Corporation· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

  NCT03011372· Phase 2· Incyte Corporation· Source